牛铭山
硕士生导师

职称：副教授

学院：第一临床医学院
msniu24@126.com







个人简介
牛铭山，博士、副教授、硕士生导师，江苏省“333工程”中青年科学技术带头人、江苏省优秀青年基金获得者、江苏省“六大人才高峰”高层次人才、江苏省“青蓝工程”优秀青年骨干教师、校青年****。主要从事白血病等血液肿瘤分子标志物筛选、发病机制与靶向治疗研究。近年，主持国家自然科学基金面上项目1项、国家自然科学基金青年基金1项、江苏省重点研发计划（社会发展）项目1项、江苏省优秀青年基金1项、江苏省自然科学基金等省部级项目5项。申请/授权国家发明专利4项，获得江苏省医学新技术引进奖一等奖1项。发表SCI收录论文40余篇，其中以第一/通讯作者在JournalofHematology&Oncology等杂志发表SCI收录论文20余篇。
欢迎有志于从事白血病等血液肿瘤研究的优秀同学报考研究生（学术型）。我们以徐州医科大学附属医院血液科和江苏省骨髓干细胞重点实验室为依托，为研究生提供优越的科研平台和科研条件，实验室具有良好的科研氛围。






发表论文:
MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-kappaB Activation

---

MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-kappaB activation

---

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

---

Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia

---

MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia

---

High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia

---

High expression of miR-338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy

---

MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy

---

Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations

---

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
教材专著:

科研项目:
靶向Myb转录因子治疗急性髓系白血病的作用与机制

---

蛋白水平修饰CARMA1调控弥漫大B细胞淋巴瘤增殖的作用机制

---

新型PML-RARA抑制剂通过自噬途径诱导APL细胞分化与凋亡的作用机制

---

新型靶向药物治疗急性早幼粒细胞白血病的转化研究

---

SUMO化调控CARMA1信号在ABC型弥漫大B细胞淋巴瘤发病中的作用及机制
获奖成果:
血液肿瘤基因分型检测新技术与分子标志物的鉴定